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Metabolic syndrome (MS) is a prevalent and severe comorbidity observed in
schizophrenia (SZ). The exact nature of this association is controversial and very
often accredited to the effects of psychotropic medications and disease-induced
life-style modifications, such as inactive lifestyle, poor dietary choices, and smoking.
However, drug therapy and disease-induced lifestyle factors are likely not the only
factors contributing to the observed converging nature of these conditions, since an
increased prevalence of MS is also observed in first episode and drug-naïve psychosis
populations. MS and SZ share common intrinsic susceptibility factors and etiopathogenic
mechanisms, which may change the way we approach clinical management of SZ
patients. Among the most relevant common pathogenic pathways of SZ and MS
are alterations in the sphingolipids (SLs) metabolism and SLs homeostasis. SLs
have important structural functions as they participate in the formation of membrane
“lipid rafts.” SLs also play physiological roles in cell differentiation, proliferation, and
inflammatory processes, which might be part of MS/SZ common pathophysiological
processes. In this article we review a plausible mechanism to explain the link between MS
and SZ through a disruption in SL homeostasis. Additionally, we provide insights on how
this hypothesis can lead to the developing of new diagnostic/therapeutic technologies
for SZ patients.
Keywords: metabolic syndrome, psychosis, schizophrenia, sphingolipids
INTRODUCTION
Schizophrenia (SZ) is a severe and chronic psychotic disorder with a lifetime risk of 0.7% (Saha
et al., 2005), in which genetic and environmental factors contribute to abnormal anatomical and
functional connectivity of the brain (Stephan et al., 2006; Canu et al., 2015). Abnormal connectivity
may be the underlying contributor to a wide range of symptoms observed in this disease, such as
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hallucinations, delusions, avolition, blunted affect, and cognitive
dysfunctions (Gaspar et al., 2012). These symptoms often cause
poor functional outcome, frequent co-morbidities, and increased
mortality rate. For these reasons, SZ is ranked among the top
10 leading causes of disease-related disability in the world and
is consistently demonstrated to have a major negative impact on
quality of life (WHO, 2001).
The well-known association between SZ and metabolic
syndrome (MS) may be a contributor to the poor long-term
outcomes stated above. The prevalence of MS among medicated
SZ patients is as high as 60%, compared to 30% in the general
population (Malhotra et al., 2013; Papanastasiou, 2013) with the
subsequent increment in cardiovascular morbi-mortality. The
nature of this association has been frequently accredited to the
adverse effects of psychotropic medications, especially second-
generation antipsychotics (Jin et al., 2004; Peet, 2004; Filakovic´
et al., 2012), and to disease-induced life-style modifications,
such as inactive lifestyle, unhealthy diet and smoking (Peet,
2004). However, several studies have shown that increased insulin
levels and glucose abnormalities can occur at early stages of
the disease, in drug naïve first episode psychosis patients (Ryan
et al., 2003; Spelman et al., 2007; Fernandez-Egea et al., 2009;
Verma et al., 2009; Guest et al., 2010; Chadda et al., 2013) and
in their first-degree relatives (Fernandez-Egea et al., 2008a,b).
It is difficult to control for all the risk factors associated to MS
(e.g., poor diet, lack of exercise, cigarette smoking, environmental
stress, and drug abuse) in observational clinical studies of SZ
patients, and indeed most studies often fail to properly control
for all of these factors. However, the study of Fernandez-Egea
et al., matched the groups by age, sex, heart rate, body mass
index, tobacco consumption, and ethnic origin (Fernandez-Egea
et al., 2009) demonstrating the plausibility of a predisposition
for developing MS among SZ patients and their close relatives.
This brings the testable hypothesis that MS in SZ patients
would not only be linked to epigenetic factors, but also to
genetic alterations, such as polymorphisms of enzymes and/or
receptors involved in brain physiology (Yogaratnam et al.,
2013).
Although there is evidence for the association of SZ with some
MS associated genes like methylenetetrahydrofolate reductase
(MTHFR) (Ellingrod et al., 2008) and alpha-1A adrenergic
receptor (ADRA1A) (Cheng et al., 2012), none of these
associations have led to a common metabolic pathway, which
actually links MS with SZ providing the rationale for research
toward a “drugable” therapeutic/prophylactic target. In this
context, it is of utmost importance to identify commonmolecular
pathways that explain this association in order to improve
current diagnostic and therapeutic strategies and to avoid major
metabolic complications.
Despite the fact that most of the current research on SZ has
been focused on the role of synaptic proteins as etiopathogenic
mediators of the disease (Stephan et al., 2009; Seshadri et al.,
2013), the interest in membrane lipids (Horrobin, 1998), and
specifically sphingolipids (SLs), has increased during the last
decade (Schwarz et al., 2008; Narayan et al., 2009). Moreover,
cumulative evidence suggests that SLs may link MS (Cowart,
2008) to psychotic disorders (Narayan and Thomas, 2011). Thus,
SLs seemingly are interesting putative candidates for common
etiopathogenic mediators of these disorders.
In this review we analyze the relevance of SLs in the
MS associated with SZ, and we also highlight molecular
events linking SZ with MS, in order to explain common
etiopathogenic mechanisms and the predisposition of SZ patients
to develop metabolic complications. Finally, according to our
perspective, we propose a unifying, testable hypothesis to explain
the participation of SLs in MS and SZ and also putative
diagnostic/therapeutic applications, based on the detection of
sub-families of SLs in peripheral samples of SZ patients.
GENERAL ASPECTS OF SPHINGOLIPIDS
SLs encompass a wide and complex family of membrane lipids
in which a fatty acid is linked to a long sphingosine carbon
backbone via an amide bond. Depending on their hydrophilic
attachments, they can be divided into three main types of
SLs: ceramides, sphingomyelins (SMs), and glycosphingolipids
(GSLs) (Figure 1). The mammalian SLs metabolism has three
major metabolic pathways: the de novo pathway coming from
saturated fatty acids, the salvage pathway, and the SMs pathway,
all of which converge in ceramides. The heterogeneous and
complex GSLs are synthesized from ceramides (Figure 2). Due
to their amphipathic properties, SLs are major components in
cell membranes and are especially ubiquitous in the central
nervous system (CNS) membrane “lipid rafts”(Colombaioni and
Garcia-Gil, 2004; Aureli et al., 2015). Since their discovery
in 1884, SLs have been shown to be involved in several
neuropsychiatric (Kolter and Sandhoff, 2006; Adibhatla and
Hatcher, 2008; Haughey, 2010), metabolic, immune, oncogenic,
and inflammatory disorders (Lahari and Futerman, 2007; Zeidan
and Hannun, 2007). Today it is widely accepted that the
biophysical and signaling properties of SLs allow them to
participate in the regulation of several key cellular processes, such
as membrane microdomains organization, allosteric modulation
of membrane proteins, and cell to cell interaction, differentiation,
proliferation, inflammation, and apoptosis (Hannun and Obeid,
2008). In fact, SLs participate in several neuronal and metabolic
processes, making them crucial to the normal and pathological
functioning of these tissues.
METABOLIC SYNDROME AND
SPHINGOLIPIDS
Metabolic Syndrome Pathophysiology
MS represents a cluster of cardiovascular risk factors including
glucose intolerance, atherogenic dyslipidemia, and hypertension,
leading to an increased risk of cardiovascular morbidity and
mortality (Isomaa et al., 2001). MS shows a tight association
with central (or visceral) fat mass, which is a good predictor of
severity for cardiovascular complications compared to peripheral
fat mass (Matsuzawa et al., 2011). This is because central fat
mass is a major source of active biomolecules, like adipokines,
cytokines, and free fatty acids (FFAs), which promote a
chronic pathological status of inflammation and oxidative stress
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FIGURE 1 | General sphingolipid structure. Sphingolipids are composed of a sphingosine backbone linked to a fatty acid via an amide bond. There are three main
types of sphingolipids, which differ in their hydrophilic attachments: ceramides, sphingomyelins, and glycosphingolipids.
(Holland et al., 2007; Kaur, 2014). Several molecular pathways
have been studied to understand the events linking central fat
mass, FFAs and MS (Holland et al., 2007), but current data do
not yet provide compelling answers. In this context, emerging
evidence demonstrates that overnutrition induces SLs synthesis
and turnover, which in turn “remodels” SLs profiles and their
topological distribution.
A plausible explanation for this is that overnutrition and
visceral obesity change FFAs profile, principally elevating levels
of saturated fatty acids (SFAs) (Holland and Summers, 2008;
Heilbronn et al., 2013; Kaur, 2014). These molecules promote
ceramides synthesis through the production of palmitate-CoA
and acyl-CoA, SFAs-derivatives involved in the de novo and
salvage pathway of SLs metabolism, respectively (Figure 2).
Palmitate-CoA is a substrate for palmitoyltransferase, the rate
limiting enzyme of the de novo synthesis pathway of ceramides,
and it stimulates palmitoyltransferase in a concentration-
dependent manner. On the other hand, acyl-CoA can increase
ceramides synthesis as a substrate of ceramides synthase
(CerS) in the salvage pathway (Figure 2; Merrill et al., 1988).
These metabolic changes increase ceramides levels, which in
turn modify intracellular signaling and promote MS-associated
conditions, like atherothrombotic status and glucose intolerance
(Cowart, 2008).
Sphingolipids and Alterations of the
Glucose Metabolism
The current literature shows that certain SLs can impair glucose
metabolism in different organs, including pancreatic, skeletal
muscle, and adipose tissues.
In pancreatic islets, lipid oversupply increases the ceramides
β-cell induced apoptosis (or “lipoapoptosis”) (Shimabukuro et al.,
1998b; Unger and Orci, 2002) In fact, pharmacological inhibitors
of the ceramides biosynthesis ameliorate the lipotoxic effect
on pancreatic β-cells (Shimabukuro et al., 1998a). Interestingly,
ceramides also inhibit the expression of pro-insulin genes
through the activation of c-Jun N-terminal kinases (JNK), an
inhibitor of kappa B kinase beta (IκKβ) (Summers, 2006). Both
mechanisms decrease pancreatic insulin secretion.
Ceramides also contribute to the glucose-resistance
phenotype in the skeletal muscle. Here, ceramides impair
glucose caption by the inhibition of the kinase B (Akt/PKB)
insulin signaling pathway (Chavez et al., 2003). This is effect
is achieved through protein phosphatase 2 (PP2A) (Zinda
et al., 2001) or protein kinase C zeta (PKCζ ) dependent
mechanisms (Bourbon et al., 2002) and also by the inhibition
of Akt translocation to the plasma membrane (Stratford et al.,
2001). Notably, in vivo studies on insulin resistant obese patients
showed increased ceramides levels in muscle biopsies (Adams
et al., 2004; Straczkowski et al., 2007) and newly discovered
evidence has identified C16:0-ceramide as the principal mediator
of obesity-related insulin resistance (Hla and Kolesnick, 2014;
Raichur et al., 2014; Turpin et al., 2014).
Finally, ceramides display other pro-inflammatory properties,
inducing inflammation in adipose tissue via tumor necrosis
factor α (TNFα) signaling (Bikman, 2012; Maceyka and Spiegel,
2014). TNFα induces insulin resistance by direct down-
regulation of the insulin-regulatable glucose transporter type
4 (GLUT-4). TNFα also acts indirectly on the glucose uptake,
by inducing the up-regulation of ganglioside GM3, which is
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FIGURE 2 | Pathways of sphingolipid metabolism. Sphingolipids have three major metabolic pathways: the de novo pathway coming from saturated fatty acids,
the salvage pathway and the sphingomyelin pathway, all of which converge in ceramides.
a member of the SLs family that has proven to inhibit both:
the insulin-mediated activation of insulin receptor substrate-1
(IRS-1) (Tagami et al., 2002) and the expression of insulin
receptors from the lipid rafts (Kabayama et al., 2005). In sum,
SLs can interrupt the insulin signaling pathway in at least four
different forms (Figure 3).
Sphingolipids and Atherothrombosis
It is important to mention that SLs synthesis is necessary for
the activation and subsequent regulation of the sterol regulatory
element-binding proteins (SREBPs), which are key transcription
factors in the lipid biosynthesis that regulate the transcription of
enzymes involved in the synthesis of cholesterol, phospholipids,
and fatty acids (Worgall et al., 2002; Worgall, 2008). Ceramides
and SMs are also implicated in the regulation of cholesterol
eﬄux by a mechanism that involves the cholesterol-eﬄux
receptors ABCA1 and ABCG1. Thus, the ABCG1-mediated
eﬄux of cholesterol is dependent on the cellular SM level in the
plasma membrane, which implies that SM influences the high-
density lipoproteins (HDL) plasma levels (Kaminski et al., 2006;
Kobayashi et al., 2006; Sano et al., 2007).
Increased levels of ceramides seem to be related to the
aggregation of low density lipoprotein (LDL) particles within the
arterial wall, as aggregated LDL particles from atherosclerotic
lesions (Guyton and Klemp, 1996) have 10- to 50-fold higher
levels of ceramides than plasmatic LDL particles (Schissel et al.,
1996). Moreover, ceramides have been shown to induce apoptosis
of cells lining the vascular wall, a process implicated in plaque
rupture of atherothrombotic disease (Mallat and Tedgui, 2001).
In parallel, S1P stimulates the proliferation of endothelial
and smooth muscle cells in the vascular walls, promoting
vascular remodeling and plaque thickening. Finally, ceramides
and S1P increase plasminogen activator inhibitor-1 (PAI-
1), an inhibitor of fibrinolysis (Soeda et al., 1995; Ito
et al., 2013), favoring platelet activation and aggregation
(Bhatia et al., 2004). Taken together, this evidence strongly
suggests that SLs, and specifically ceramides, are crucial in
the pathophysiology of the atherothrombotic process and
cardiovascular events in obese, overfed, or malnourished patients
(Figure 3).
Interestingly, obesity and alterations of the lipid
metabolism have also been associated with psychotic disorders
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FIGURE 3 | Relationship between visceral obesity, sphingolipids, and metabolic abnormalities. Saturated fatty acids are included in the sphingolipid
pathways and are synthesized to ceramides. Ceramides affect the insulin signaling pathway and favor the atherothrombotic process through different metabolic
pathways.
(Oresic, 2012). This topic will be reviewed in the next
section.
HEALTHY CENTRAL NERVOUS SYSTEM
AND SPHINGOLIPIDS
Lipids in the brain account for 60% of its dry weight (Horrobin,
1998), and SLs in particular are found in high concentrations
in the membranes of neurons and oligodendrocytes (van
Echten-Deckert and Herget, 2006; Piccinini et al., 2010).
This peculiar lipid composition and concentration favors
the organization of laterally organized lipid-driven membrane
domains. In fact, SLs have functional properties in inflammatory
responses, and also structural properties as precursors of
SMs and GSLs, which are necessary for the formation
of the specialized membrane “lipid rafts” in neurons and
oligodendrocytes myelin sheaths (Aureli et al., 2015). Lipid
rafts are important for cell-to-cell interactions and modulation
of membrane-associated proteins which determine normal
synaptic neurotransmission (Allen et al., 2007) and axon-
myelin stability and communication (Aureli et al., 2015). Due
to these biologically critical features, SLs are a vital factor
in the normal functioning of neurons and oligodendrocytes,
determining appropriate axonal/synaptic connectivity, and
neuronal survival (Posse de Chaves, 2006). In fact, the
absence of the complex GSL synthesis function during early
neurodevelopment stages is lethal in animal models (Jennemann
et al., 2005).
SCHIZOPHRENIA PATHOPHYSIOLOGY
SZ is assumed to be a neurodevelopmental disorder in which
genetic and environmental factors contribute to abnormal
neuronal (Stephan et al., 2006; Kahn and Sommer, 2015) and
glial cell (Hakak et al., 2001; Tkachev et al., 2003; Goudriaan
et al., 2014; Bernstein et al., 2015) histology and function, leading
to specific white matter and synaptic abnormalities that impair
anatomical and functional brain connectivity.
Although the initial SZ pathognomonic events are unknown,
a plausible inflammatory hypothesis states that environmental
stress during early childhood (e.g., perinatal infections)—
on top of increased genetic vulnerability—may stimulate
the immune system to secrete pro-inflammatory cytokines
contributing to subclinical but long-lasting neurotoxic
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processes. Current evidence supports the hypothesis that chronic
inflammation impairs the monoaminergic and glutamatergic
normal neurotransmission and damages white and gray matter
structures in SZ patients (Müller et al., 2015; Najjar and
Pearlman, 2015).
In fact, neuropathological studies in brains of SZ patients
have shown that neuronal density increases, but glial density and
dendritic spines decreases (Davis et al., 2003; Garver et al., 2008;
Kyriakopoulos et al., 2008; Bakhshi and Chance, 2015; Gong
et al., 2016). Other studies have also demonstrated that SZ brains
display alterations in the expression of presynaptic proteins
(e.g., increased SNARE interactions) and in the oligodendrocyte
myelin sheet lamella (Bakhshi and Chance, 2015; Ramos-Miguel
et al., 2015). There is also evidence of reduced brain weight and
volume in a various brain regions, along with cerebral ventricular
enlargement, loss of cerebral asymmetry, and reduction of
fronto-temporal white matter tracts, all of which would impair
structural connectivity of the brain (Stephan et al., 2006; Canu
et al., 2015). Although there are other plausible hypotheses to
explain the functional brain disconnection in SZ, we highlight a
convergent hypothesis that explains the functional consequences
of these heterogeneous synaptic and axonal anomalies based on
the hypofunction of N-methyl-D-aspartate (NMDA) receptors
in parvalbumin-positive γ-aminobutyric acid (GABA)-ergic
interneurons. This abnormal NMDA signaling could lead to
the disruption of the cortical tuning of glutamatergic pyramidal
neurons. This hypofunction would cause a disengagement of the
cortico-cortical and cortico-subcortical networks, impairing the
functional connectivity of different brain areas (Ford et al., 2007;
Gaspar et al., 2009, 2012; Uhlhaas and Singer, 2010; Gonzalez-
Burgos and Lewis, 2012; Woodward et al., 2012; Cao et al.,
2016).
Thus, inflammation and the loss of normal axonal or
synaptic connectivity are seemingly responsible for the cognitive
impairments and other classical symptoms (hallucinations,
delusions, negative, and affective symptoms) observed in this
disease, leading to the major social difficulties seen in these
patients.
SCHIZOPHRENIA AND SPHINGOLIPIDS
Numerous studies have shown alterations of the membrane
lipid composition (Horrobin, 1998) and SLs metabolism in SZ
(Yao et al., 2000; Schwarz et al., 2008; Narayan et al., 2009;
Smesny et al., 2013) and other neuropsychiatric diseases (Posse
de Chaves, 2006; Adibhatla and Hatcher, 2008; Jana et al., 2009;
Kornhuber et al., 2009; Haughey, 2010; Mielke et al., 2010;
Narayan and Thomas, 2011; Mühle et al., 2013; Saito and Saito,
2013). Due to their functional and structural roles, SLs could
explain in part the inflammatory, synaptic and white matter
changes that leads to disconnectivity in SZ (Jana et al., 2009;
Please see Boxes 1, 2 for further discussion of SL abnormalities
and their distribution across the central nervous system). Here
we discuss how the clinical data and several model systems
provide evidence on the abnormalmetabolism of SLs and its close
connections with neuroinflammation and disconnectivity in SZ.
Sphingolipids and Schizophrenia
Inflammatory Hypothesis
Some SLs have pro-inflammatory properties (Maceyka and
Spiegel, 2014) that can be involved in the initiation and
maintenance of the subclinical inflammatory status linked to
the above mentioned “neurodevelopmental vulnerability-stress-
inflammatory model of SZ” (Müller et al., 2015). Moreover, SLs
have also pro-apoptotic properties which suggest a plausible
neurodegenerative component of SZ. Although SZ is not
classified as a neurodegenerative disorder, it is clear that the
progressive deterioration of some SZ subjects derives from
incomplete apoptotic mechanisms at the local synaptic level
(without inducing immediate neuronal death; Jarskog et al.,
2005). Thus, SLs may be involved in both: pro-inflammatory and
pro-apoptotic pathways.
In agreement with these plausible mechanisms, postmortem
studies have found a significant decrease of phosphatidylcholine
(PC) in the white matter of SZ patients (Yao et al., 2000). PC
is the choline donor to SMs in neurons and oligodendrocytes.
Therefore, low levels of PC are related to decreased SMs
BOX 1 | Sphingolipid abnormalities in specific brain areas.
Despite the fact that SLs-related neuropathological alterations have been linked to specific brain areas (e.g., prefrontal Cortex or thalamus), it is still difficult to reach
coherent conclusions that can help to further understand this conundrum, if we are only based on the expression profiles of SLs-related enzymes. For instance,
it is known that the six ceramide synthase (CerS) subtypes are differentially expressed through the nervous system. CerS determine the acyl-chain length of SLs,
thus each tissue/cell has distinct SL acyl-chain length profiles. As an example, in the brain, CerS1 (which targets C18 acyl-chains) is distributed primarily in neurons,
whereas CerS2, responsible for the synthesis of C22-C24 acyl-chain SLs, is expressed specifically in oligodendrocytes and Schwann cells. Several studies suggest
that SLs with defined acyl-chain lengths play distinct pathophysiological roles in disease models (Park et al., 2014; Park and Park, 2015) and the alterations in the
relative balance of these species might be of pathogenic relevance in SZ.
BOX 2 | Sphingolipid abnormalities in the peripheral nervous system.
If SZ patients suffer from a genetic SLs metabolism vulnerability, we should also expect peripheral neurologic abnormalities that go far beyond central nervous system
dysfunctions. In fact, there is evidence of abnormal peripheral neuromuscular functioning in SZ patients, which supports the idea of SZ as a generalized disease
rather than a specific central nervous system problem. For instance, there are alterations of the α-motoneuron excitability, increased motor unit fiber densities and
increased branching of terminal motor nerves to elevated levels of muscular enzymes (Flyckt et al., 2000). Moreover, there is electrophysiological evidence on the
functional consequences of these abnormalities showing impaired peripheral impulse propagation in electromyographic recordings (Borg et al., 1987). All of these
findings are compatible with membrane defects.
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levels and, eventually, increased turnover of SMs to ceramides
(Posse de Chaves, 2006). These findings may be associated with
oligodendrocyte dysfunction, since SMs is a major component
of myelin sheaths and ceramides have an apoptotic and
inflammatory role.
Neuropathological evidence shows increased levels of
phosphatidylserine in the left thalamic gray matter of SZ patients
(Schmitt et al., 2004). This suggests the presence of a ceramides-
mediated cell death, because phosphatidylserine acts as a potent
activator of neutral sphingomyelinase (Sawai and Hannun, 1999)
and stimulates phagocytosis of apoptotic cells (Chang et al.,
2000).
Consistent with the previous findings, bipolar disorder,
and SZ patients are reported to show significantly increased
levels of ceramides and decreased levels of PC in their
white matter, regardless of antipsychotic treatment (Schwarz
et al., 2008). Remarkably, environmental stress (such as
psychoactive substances and oxidative stress) that are known
to be involved in the development of several psychiatric
disorders, also activate sphingomyelinase, increasing pro-
inflammatory metabolites like ceramides and its derivatives
(Posse de Chaves, 2006; Jana et al., 2009; Mühle et al., 2013)
(Figure 4).
Sphingolipids and the Schizophrenia
Disconnectivity Hypothesis
Genetic studies in humans and animals provide additional
evidence for the role of abnormal SLs metabolism in the SZ
disconnectivity hypothesis. Genes related to the metabolism of
some structural SLs, such as SMs and GSLs, are altered in subjects
with SZ, which might impair normal neuronal or glial function.
The article of Narayan et al. is of particular interest in this
context, as it shows decreased expression of UGT8-encoding
for galactosyltransferase (CGT) and GAL3ST1–encoding for
cerebroside sulfotransferase (CST) in these subjects. CGT is
responsible for converting ceramides to galactosylceramides,
and CST is responsible for the further metabolization of
galactosylceramides to sulfatides. Diminished expression of
these two genes may result in the overall decreased levels
of galactosylceramides and sulfatides, which are major lipid
components of the oligodendrocyte myelin sheath (Narayan
et al., 2009) (Figure 4).
Interestingly, investigations with animal models confirm the
in vivo consequences of these GSL pathologies. In fact, mice
lacking CGT form unstable and functionally affected myelin and
exhibit progressive demyelination, accompanied by severe motor
coordination deficits (Zöller et al., 2005). Another study shows
FIGURE 4 | Relationship between sphingolipids and schizophrenia. There are at least three different described ways by which abnormal sphingolipid
metabolism could impair normal neural functioning in humans: (1) By abnormal expression of galactosylceramide synthase increasing ceramides and decreasing
galactosylceramides in myelin sheaths. (2) Stimulation of sphingomyelinase by stress factors, leading to a breakdown of sphingomyelins to ceramides. (3) And finally,
by decreased synthesis of phosphatidylcholine. All of these mechanisms impact normal lipid membrane properties and might induce the synaptic and axonal
disconnectivity seen in schizophrenia.
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that the administration of GM1 ganglioside fully restored the
mice’s MK801-SZ cognitive model, correcting cognitive deficits
and the impaired BDNF signaling (Ni et al., 2016). Finally,
there is evidence that the induction of catalytically inactive SLs
enzymes induces cognitive and behavioral abnormalities. For
example, some inactive CerS-specific subtypes induce myelin
sheath GSLs and glycoprotein defects, as well as behavioral
abnormalities that include motor, exploration and habituation
deficits (Imgrund et al., 2009; Ginkel et al., 2012; Ebel et al., 2013).
Perhaps findings observed in first-episode SZ patients with lower
levels of ceramide 1 (a long chain ceramide) and higher levels of
ceramides 5 and 8 (short chain ceramides) may be explained in
this context (Smesny et al., 2013).
One potential explanation for these behavioral consequences
is a membrane microdomain destabilization due to a lack of
structural SLs. As suggested above, membrane “lipid rafts” are
mostly formed and regulated by SLs. This is important for
axonal-glial (Figure 5) and synaptic interactions, both crucial
for proper brain connectivity (Jackman et al., 2009). In this
context, the study by Colón-Sáez and Yakel reported that the
enzymatic hydrolysis of SMs in rat hippocampal neurons alters
the α-7 nicotinic acetylcholine receptor function, presumably
influencing its anchoring in the lipid rafts (Colón-Sáez and Yakel,
2011).
Overall, the discussed evidence supports the hypothesis
that SZ disconnectivity can be explained by alterations
in membrane SLs metabolism, which lead to a decreased
axonal myelination and impaired synaptic plasticity
(Figure 5).
Future of Sphingolipids in the Development
of New Diagnostic and Therapeutic
Technologies for Schizophrenia-Related
Metabolic Syndrome
For a long time, clinicians have speculated about the potential
options to exert therapeutic interventions during the early stages
of SZ, with the goal of delaying or averting the illness and/or
its complications (Sullivan, 1994; Srihari et al., 2013). However,
effective early interventions require the ability to correctly
identify the patients that will have a poor clinical course andmore
comorbid conditions, like MS.
Even though international clinical guidelines recommend
undertaking a complete cardiovascular risk assessment in first
episode psychosis patients before pharmacological treatment is
initiated (De-Hert et al., 2009), the routine metabolic screening at
early stages does not consider a MS genetic vulnerability. In fact,
we do not have clinically validated biomarkers for the diagnosis
or follow up of SZ, nor its metabolic complications (Weickert
et al., 2013). Thus, it is still a challenge to select a particular
subpopulation of SZ patients to follow.
Emerging evidence suggests that SLs may be suitable
biomarkers forMS, revealing important associations betweenMS
and the level of certain SLs in peripheral blood samples. There are
FIGURE 5 | Schematic representation of the participation of membrane glycosphingolipid-enriched microdomains in schizophrenia. The repartitioning of
molecules into (or out of) lipid rafts can lead to an impaired myelin structure in oligodendrocytes and impaired synaptic connectivity in neurons. In this example,
oligodendrocytes myelin-associated glycoprotein (MAG) and myelin/oligodendrocyte glycoprotein (MOG) are segregated from the lipid raft following a structural
sphingolipid abnormality, leading to an insufficient axonal-glial interaction and loss of brain connectivity.
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at least six studies that show elevated levels of ceramides or GM3
gangliosides in overfed, overweight or diabetic/dyslipidemic
patients in peripheral samples. Additionally, these abnormalities
are usually correlated with elevation in other parameters, such
as adiponectin, cholesterol, TNFα and glucose (Sato et al., 2008;
Majumdar and Mastrandrea, 2012; Heilbronn et al., 2013; Lopez
et al., 2013; Ng et al., 2015; Veillon et al., 2015) (Table 1).
These results are paralleled by similar findings in an overfed and
diabetic primate model (Brozinick et al., 2013).
There is also evidence showing association between SZ
and SLs levels in peripheral samples (Table 1). Schwarz et al.
demonstrated elevations of specific ceramides (C34:1) and FFAs
(stearic acid) in peripheral red blood cell samples from SZ
patients after using second-generation antipsychotics (Schwarz
et al., 2008). The study of Smesny et al. (See Table 1) supports
a SZ-SLs direct association, since they found SLs abnormalities
in the stratum corneum of the skin of first-episode drug-
naïve SZ patients, representing a novel and non-invasive test
for psychiatric diagnosis (Smesny et al., 2013). The rationale
behind this approach is the large representation and structural
homology between skin and CNS lipids. In this case, the
researchers found only ceramides abnormalities among different
classes of skin lipids. Lastly, other studies have found decreased
PC, which might be related to increase SMs breakdown and
thus increased ceramides levels in SZ patients (Brozinick et al.,
2013).
Whether the association between SLs and SZ is related to only
a specific subpopulation of SZ patients at risk to develop MS
is still unknown, and future longitudinal studies are necessary
in this area. Due to the importance of SLs metabolism in
neurodevelopment and in general lipid homeostasis, it is also
necessary to explore whether SLs alterations in MS and SZ are
indicating a common pathophysiological alteration with different
phenotypic manifestations. In this regard, it will be important to
recruit SZ patients without central obesity for new studies, so
as to demonstrate that metabolic disturbances are independent
from classical MS mechanisms in these patients.
Although the presented studies have diverging purposes,
subjects and results, there are relevant common conclusions,
which can support the relationships between SZ and SLs
metabolism. First, it is possible to measure significant alterations
in SLs in peripheral samples like blood and skin cells, which may
reflect actual SLs alterations in CNS and other tissues. This is
important since it opens the possibility for developing an ideal
non-invasive biomarker for a SNC condition. Second, although it
is still necessary to have more compelling evidence with proper
controls for all MS risk factors, current literature suggest that
MS is also present in young antipsychotics-free populations
regardless of disease progression and pharmacological treatment.
Finally, although the current studies have focused on the analyzes
of different subtypes of lipids in biological samples, which make
data comparability rather difficult, all of them suggest that the
inflammatory/structural ratio of SLs ratio is increased, as a
commonmetabolic feature of SZ andMS. This is interesting if we
consider that both, SZ and MS, correspond to complex polygenic
alterations and gene-environment interactions. Perhaps a
hypo/hyperfunction of some SLs-related enzymes may trigger
these abnormalities.
TABLE 1 | Sphingolipids, and other related lipids in peripheral samples as biomarkers of schizophrenia or metabolic syndrome in humans.
References N Subjects Gender Age Sample Main Findings
SCHIZOPHRENIA STUDIES
Schwarz et al., 2008 20 First episode and chronic Both 36.85 ± 8.4 Blood (red blood cells) ↑Cer 34:1 and stearic acid under SGA
treatment.
Smesny et al., 2013 28 First episode Both 23.27 ± 3.6 Skin (stratum corneum) ↓Total Cer, ↑Cer AH and NH/AS, ↓Cer
EOS and NP.
He et al., 2012 265 Chronic Both 19–67 Blood (Plasma) ↓PC C38:6.
METABOLIC SYNDROME STUDIES
Heilbronn et al., 2013 40 Overfed Both 37 ± 2 Blood ↑Total Cer, C22:0 and C24:0 (correlated
with LDL).
Lopez et al., 2013 14 DM2 Female 14.3 ± 1.8 Blood (Plasma) ↑Cer C22:0, C20:0, C18:0, and C24:1
DihydroCer (correlated with adiponectin,
HOMA-IR, BMI, fasting glucose, TG).
Majumdar and
Mastrandrea, 2012
30 Overweight Both 14.6 ± 1.2 Blood (Serum) ↑Cer correlated with TNF-α, adiponectin,
lipoproteins, and HOMA-IR levels.
Ng et al., 2015 12 MS Men 48.6 ± 8.5 Blood (Plasma) VLDL apoB-100 directly correlated with
longer chain Cer concentrations (C20:0,
C22:0, C24:1, C24:0).
Veillon et al., 2015 39 Visceral fat ±
hyperglycemia/dyslipidemia
Both 52.1 ± 1.5 Blood (Serum) ↑GM3 species. GM3 d18:1-h24:1 was the
best candidate for metabolic screening.
Sato et al., 2008 55 DM2 and hyperlipidemic Both 31–84 Blood (Serum) ↑GM3 species. GM3 was directly
correlated with LDL.
↓, decreased levels; ↑, increased levels; Cer, ceramides; MS, metabolic syndrome; AH, α-hydroxy 6-hydroxysphingosine; NH, nonhydroxy 6-hydroxysphingosine; AS, α-hydroxy
sphingosine; EOS, ω-hydroxysphingosine; NP, nonhydroxy phytosphingosine; HOMA-IR, insulin resistance homeostasis model assessment; TNF-α, tumor necrosis factor α; PC,
phosphatidylcholine; SGA, second generation antipsychotics; DM, diabetes mellitus; TG, triglycerides; GM3, ganglioside GM3; LDL, low density lipoprotein; VLDL, very low density
lipoprotein; BMI, body mass index.
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Consequently, we propose the testable hypothesis that a
specific SLs profile from peripheral tissues will serve as a MS
biomarker to diagnose and evaluate the natural evolution of
MS in psychotic patients. Since SZ is a highly heterogenic
disease, this biomarker should allow us to recognize a differential
vulnerability for metabolic disturbances among SZ patients. In
this context, prodromal and first-episode psychosis populations
represent a good and early opportunity to make a complete
evaluation in order to target specific preventive interventions for
these patients.
Finally, it is worth mentioning in this review that many
of the emerging alternative treatments proposed for SZ [e.g.,
vitamins (Arroll et al., 2014; Brown and Roffman, 2014),
omega-3 fatty acids (Hashimoto et al., 2014), anti-inflammatory
agents (Girgis et al., 2014)] can have direct and/or indirect
impacts on inflammatory status, membrane lipids profiles, and
membrane structural properties (Yaqoob and Shaikh, 2010).
Omega-3 fatty acids in particular have important effects on brain
functions since docosahexaenoic acid (DHA) is amajor structural
component of phospholipids in neuronal cell membranes
and eicosapentaenoic acid (EPA) shows neurotransmitter and
neuromodulatory activity (Fenton et al., 2000) which may have
therapeutic properties in psychotic symptoms. In fact, recent
evidence has confirmed that young adults with sub-threshold
psychotic symptoms lower their risk of developing a psychotic
disorder when treated for 12 weeks with a formulation containing
omega-3 essential polyunsaturated fatty acids (PUFAs), EPA,
DHA, and tocopherol (Vitamin E) (Amminger et al., 2010, 2015).
This opens new possibilities to investigate the specific role of
SLs metabolism in SZ, with the goal of finding new therapeutic
opportunities in SZ.
CONCLUSIONS
In summary, we have reviewed the evidence linking SLs, MS, and
SZ, hinting a plausible common etiopathogenic a mechanism,
which explains the clinical features like the vulnerability of
these patients to develop metabolic complications, regardless
of the presence of antipsychotic drugs, at early stages of
the disease. Moreover, dysfunction in SLs pathway may
represent an important connecting-piece in understanding the
FIGURE 6 | Sphingolipids as the central convergence point between metabolic syndrome and schizophrenia. Environmental factors and intrinsic genetic
vulnerability converge in an abnormal sphingolipid metabolism, in this case represented in an increased inflammatory/structural sphingolipid ratio. This alteration might
lead to both metabolic and neuronal abnormalities secondarily provoking cardiovascular morbidity and psychotic symptoms.
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SZ neurobiology, allowing us to link the current diverse theories
of SZ pathology (Figure 6).
As suggested above, measuring specific levels of SLs in
biological samples and defining a specific profile of these
molecules in skin tests or in peripheral blood samples could help
us to anticipate cardiovascular complications and/or to make
an early SZ diagnosis, especially in the group of patients at
prodromal and first episode of psychosis. By using SLs profiles as
MS and/or SZ biomarkers in this population, we could develop a
more personalized clinical management to improve the patient’s
prognosis. Finally, this association opens new possibilities for
innovative research in the SLs field toward finding novel
pharmacological treatments such as omega-3 fatty acids, which
may impact both psychotic and/or metabolic symptoms.
Future studies should confirm these statements in order to
find the most representative profile of SLs involved in SZ and to
prove the feasibility and clinical utility of these examinations.
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NOMENCLATURE
ADRA1A= Alpha-1A adrenergic receptor
Akt/PKB= Protein Kinase B
BDNF= Brain-derived neurotrophic factor
CerS= Ceramide Synthase
CGT= Galactosyltransferase
CNS= Central Nervous System
CST= Cerebroside Sulfotransferase
DHA= Docosahexaenoic acid
DTI= Diffusion Tensor Imaging
EEG= Electroencephalogram
EPA= Eicosapentaenoic acid
FFAs= Free Fatty Acids
fMRI= Functional Magnetic Resonance Imaging
GABA= Gamma-Aminobutyric Acid
GLUT-4= Glucose Transporter Type 4
GSLs= Glycosphingolipids
HDL=High Density Lipoprotein
IRS-1= Insulin Receptor Substrate-1
IκKβ= Inhibitor of kappa B Kinase beta
JNK= c-Jun N-Terminal Kinases
LDL= Low Density Lipoprotein
MS=Metabolic Syndrome
MTHFR=Methylenetetrahydrofolate Reductase
NMDA= N-methyl-D-aspartate
PAI-1= Plasminogen Activator Inhibitor-1
PC= Phosphatidylcholine
PI3K= Phosphoinositide 3-kinase
PKCζ = Protein Kinase C zeta
PP2A= Protein Phosphatase 2A
PUFAs= Polyunsaturated fatty acids
S1P= Sphingosine-1-Phosphate
SFAs= Saturated Fatty Acids
SLs= Sphingolipids
SMs= Sphingomyelins
SREBPs= Sterol-Regulatory Element Binding Proteins
SZ= Schizophrenia
TNF-α= Tumor Necrosis Factor α
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